Exforge Group News Today

Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core operating

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis continues to grow with further core margin expansion and achieves important innovation milestones

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating

Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven by key growth brands including: Entresto (+31% cc), Kesimpta

Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Novartis Pharma AG: Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged. Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Oncology BU grew +7% (cc, +11% USD) driven by Promacta/Revolade (+18% cc), Sandoz grew +5% (cc, +11% USD) as the business is starting to stabilize Excluding prior year forward purchasing de-stocking, we estimate Q2 net sal...

COVID-19 update The COVID-19 situation continues to evolve and is taking differing courses across the multitude of geographies in which Novartis operates. We continue to take strong actions to help address the pandemic. Our primary concerns remain the health and safety of our associates and patients. There continues to be COVID-19 related lockdowns and disruptions in several geographies negatively impacting demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Re...

Novartis International AG: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020. Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Cosentyx (+13% cc), Xiidra acquisition (+95% cc) Promacta/Revolade (+23% cc), Piqray (reaching USD 0.3 billion) Sandoz sales were in line (cc, -1% USD), with Biopharmaceuticals growing 19% (cc) COVID-19 negatively impacted demand, particularly: ophthalmology, dermatology and Sandoz retail Cor...